

March 11, 2022

Market Outlook

Indian markets are likely to open on a negative note tracking weak global cues after investors cheered results of assembly polls in five states. Also, investors continue to monitor newsflows on the Russia-Ukraine war closely.

Markets Yesterday

- Domestic markets ended higher on the back of gains across BFSI, auto, pharma and IT stocks amid sharp fall in crude prices and a decisive victory for the BJP in UP elections
- US markets ended lower amid release of macroeconomic data and very little progress in Russian-Ukrainian peace talks


Key Developments

- According to Knight Frank India, monthly residential property registrations in Hyderabad were at 5,146 units in February 2022, worth ₹ I 2,722 crore with ~74% of all sales registered in February in homes between 1,000 and 2,000 sq ft. Additionally, the weighted average transacted price of residential properties has grown by 21% YoY in February 2022 with price hike and largely due to mix change towards bigger sized units
- Large central public sector entities have achieved ~80% of their aggregate capital expenditure target for FY22 by February-end, by investing ₹ 4.72 lakh crore. NHAI was the top investor with a capex of ₹ 1.42 lakh crore, or 108% of its FY22 target. Indian Railways was lagging behind NHAI as it achieved 68% of the FY22 target of ₹ 1.95 lakh crore in the first 11 months of the year
- As per media reports, RIL has sold CBM gas for US\$23.5/mmbtu in recent auction. The total quantity sold is 0.65 mmscmd. The company has received high premium for the same

Nifty Hea	at Map								
HUL	2,102 5.2%	Tata Steel	1,309 4.2%	Grasim Ind	1,555 4.1%	SBI	469 3.8%	JSW Steel	651 3.8%
Tata Consum	724 3.6%	100	121 3.4%	Tata Motors	420 3.4%	Indusind Bank	904 3.3%	Britannia	3,223 3.2%
Axis Bank	695 3.1%	Bajaj Finserv	15,467 3.0%	Nestle	17,649 2.9%	Maruti	7,212 2.6%	Bajaj Auto	3,422 2.5%
SBI Life	1,050 2.4%	Adani Ports	730 2.3%	L&T	1,728 2.2%	HDFC Ltd	2,238 2.0%	BPCL	349 1.9%
Bajaj Finance	6,585 1.7%	Reliance Ind.	2,392 1.6%	Divis Lab	4,301 1.6%	HDFC Bank	1,393 1.6%	Titan	2,468 1.4%
ICICI Bank	677 1.4%	Hero Moto	2,321 1.3%	Asian Paints	2,913 1.3%	HDFC Life	521 1.3%	ITC	232 1.2%
NTPC	133 1.1%	Shree Cement	22,198 1.1%	Hindalco	594 1.0%	Bharti Airtel	698 0.9%	Kotak Bank	1,754 0.9%
HCL Tech	1,192 0.8%	Infosys	1,826 0.7%	Ultratech	6,053 0.6%	Cipla	987 0.6%	M&M	739 0.5%
Wipro	588 0.5%	Eicher	2,303 0.4%	Power Grid	209 0.4%	Sun Pharma	870 0.1%	UPL	724 -0.1%
TCS	3,621 -0.3%	ONGC	174 -0.6%	Dr Reddy	3,893 -1.0%	TechM	1,485 -1.3%	Coal India	179 -4.1%

Today's Highlights

Events: India manufacturing output, India industrial production



Sensex Nifty	16,595	16,345	1.5	-1.4 -1.2	-4.8 -4.4	22.3
Institut	ional Activ	rity				


Institutional Activity									
	CY20	CY21	YTD CY22	Yesterday	Last 5 Days				
FII (₹ cr)	64,379	-95,085	-1,28,105	-1,981	-34,719				
DII (₹ cr)	-28,544	95,934	92,655	946	24,635				

World Indice	World Indices – Monthly performance								
Kospi	Shanghai	NSE	Dow Jones	BSE					
2,680	3,296	16,595	33,174	55,464					
-3.2%	-5.4%	-5.7%	-5.9%	-5.9%					
Nikkei	U.K.	Nasdaq	France	Germany					
25,690	7,099	13,130	6,207	13,442					
-7.2%	-7.3%	-7.4%	-11.5%	-13.2%					


Markets Today (I	Jpdated till Ye	esterday)			
Commodities	Close	Previous	Chng (%)	MTD(%)	YTD(%)
Gold (₹/10 gm)	53,225	52,745	0.9	4.9	10.7
Silver (₹/kg)	70,303	69,575	1.0	8.3	12.2
Crude (\$/barrel)	117.3	111.1	5.6	16.2	50.8
Copper (\$/tonne)	9,964	10,161	-1.9	0.5	2.3
Currency					
USD/INR	76.3	76.0	0.3	-1.3	-2.6
EUR/USD	1.1	1.1	-0.4	-1.6	-2.9
USD/YEN	116.0	116.1	-0.1	-0.8	-0.8
ADRs					
HDFC Bank	59.1	55.3	7.0	-4.9	-9.2
ICICI Bank	17.9	16.8	6.5	-8.1	-9.6
Tata Motors	26.6	24.9	7.0	-12.1	-17.0
Infosys	23.9	23.3	2.4	6.4	-5.6
Dr Reddys Labs	51.5	50.4	2.1	-3.7	-21.3
Wipro	7.6	7.5	1.6	4.3	-22.1




Key Data Points			
Key Economic Indicator	Period	Latest	Prior Values
RBI Cash Reserve Ratio	N/A	3.00%	4.00%
RBI Repo Rate	N/A	4.00%	4.00%
RBI Reverse Repo Rate	N/A	3.35%	3.35%
CPI YY	Jan	6.10%	5.59%
Current Account Balance	Ω2	-9.6bln \$	6.5bln \$
Exports - USD	Jan	34.5bln\$	30.04 bln\$
FX Reserves, USD Final	Jan	634.28 bln\$	635.08 bln\$
GDP Quarterly yy	Q3	5.40%	8.40%
GDP Annual	FY21	-7.30%	4.20%
Imports - USD	Jan	51.93 bln \$	52.94 bln \$
Industrial Output yy	Jan	0.4%	1.3%
Manufacturing Output	Jan	0.0%	0.9%
Trade Deficit Govt - USD	Jan	-17.42 bln \$	-21.7 bln \$
WPI Food yy	Jan	9.6%	9.2%
WPI Fuel yy	Jan	32.3%	32.3%
WPI Inflation yy	Jan	13.0%	13.6%
WPI Manuf Inflation yy	Jan	9.4%	10.6%









Key News for To	oday		
Company/I ndustry	News	View	Impact
IGL	According to CNBC, IGL has got authorisation for the development of the city gas distribution network in the geographical area of Banda, Chitrakoot and Mahoba in Uttar Pradesh	(including one in 11th CGD round). Licenses for additional geographical areas	

Exide

Exide, in a regulatory filing informed the Such a development comes as a positive exchange about its long-term technical news for the company as SVOLT has collaboration with SVOLT Energy Technology capabilities across battery materials, cells, (China) for lithium-ion cell manufacturing. As modules, packs and battery management part of the agreement, SVOLT will grant Exide systems for automobile as well as energy an irrevocable right and license to use and storage applications. It is known for commercialise necessary technology and developing cobalt-free Li-on battery for know-how owned by them for lithium-ion cell mobility solutions. SVOLT aims to achieve manufacturing in India. Additionally, SVOLT a production capacity to \sim 200 GWh by will also provide the support required to set 2025. SVOLT is a sister concern of Great up a greenfield manufacturing plant on a Wall Motors, which has a prominent turnkey basis. The company also notified that presence across the battery electric space it is in fairly advanced stages of discussions in the passenger vehicle category for finalising the land parcel for this facility and has also applied under PLI scheme on Advanced Chemistry Cell (ACC)



Larsen Toubro (L&T)

contracts (ranging from ₹1000-2500 crore), capex recovery theme in India given its including specialty hospital. The Railways strong execution capability, presence SBU has secured an EPC order of Ircon across diverse sectors and geographies, International. The order comprises 25 kV which makes it less vulnerable during overhead electrification, telecommunication works for 549 RKM, 678 non-core assets, improving RoEs and TKM railway lines in the Northeast Frontier reducing debt make it an attractive Railway. The project is part of the central portfolio bet to ride the infrastructure and 'Mission initiative aimed to electrify the entire Indian Railway network. Ircon International is the implementing agency for the Electrification works for select networks of Indian Railways. The company's factories business secured an order from an FMCG manufacturer for a food processing facility in Gujarat. The scope involves civil, structural, architectural and Mechanical, Electrical and plumbing (MEP) utility works including external development works. Besides, L&T has secured an order to expand a specialty hospital in Kolkata with 250 beds. The built-up area of the project is 2.61 lakh square feet

& L&T Construction has received three new L&T remains the best way to play the signalling and down cycles. Focus on monetisation of Electrification' manufacturing cycle revival theme





ICICI Direct Research

Zydus Lifescience

Gujarat underwent a USFDA inspection from critical site for the US injectable business February 24 to March 10, 2022. The amid existing warning letter for Moraiya inspection closed with three observations facility. Zydus aims to create a US\$250 from USFDA

Zydus Lifesciences' injectable facility at Jarod, The injectable facility at Jarod, Gujarat is a million plus franchise on injectable front in three years. However, with both Moraiva and Jarod facility under regulatory noncompliance, key launches of transmerdal portfolio and complex injectables is likely to get affected




Key developments (Continued...)

- As per IQVIA data, the domestic pharma market grew 3% and 19% YoY for the month and MAT level in February 2022, respectively. Leading therapy-wise YoY growth for February 2022 - respiratory:16%, antiinfectives:4%, cardiac:4%, neuro:4% and pain:4%. Notable company-wise YoY growth for February 2022 were - P&G Health: 21%, Ipca: 9%, Zydus: 8%, Sun: 5%, Abbott: 5%, Glenmark: 5% and Ajanta: 5%
- Lupin has launched its first reference laboratory in East India in Kolkata with capabilities to conduct a broad spectrum of routine and specialised tests in the fields of molecular diagnostics, cytogenetics, flow cytometry, histopathology, cytology, microbiology, serology, haematology, immunology and routine biochemistry. Lupin Diagnostics is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Odisha to comprehensively cater to the East India region. These labs will be connected to Lupin's franchise collection centres (100 plus enrolled for East India operations)
- As per bulk deal data on BSE, Coforge promoter Hulst BV has offloaded 60 lakh shares (10% stake) amounting to ₹ 2,560 crore. The promoter stake has now come down to 39% as a result of this deal vs. 49% in December 2021 and 64% in December 2020. Additionally, Nomura India Investment Fund and Societe Generale have picked up 476,000 and 486,000 shares of the company, respectively. Nomura India fund now owns 1.9% stake in the company after this transaction
- As per Times of India, Adani Total Gas has hiked CNG price by ₹ 2/kg to ₹ 73.1/kg in the Ahmedabad area
- Bank credit grew 7.9% to ₹ 116.27 lakh crore and deposits rose 8.6% to ₹ 162.17 lakh crore in the fortnight ended February 25, RBI data showed. In the previous week ended February 11, 2022, bank credit grew 7.86% and deposits by 9.11%. In the fortnight ended February 26, 2021, bank advances were at ₹ 107.75 lakh crore and deposits at ₹ 149.33 lakh crore
- According to Business Standard, State Bank of India will revamp its banking application "YONO" and position it as a complete digital bank under new rubric "ONLY YONO" for enhancing customer experience and ease of use. It plans to rope in a consultant to help to draw the project plan keeping in mind business goals for the next five years. With 5.4 lakh monthly active users (MAUs), SBI YONO has seen growth of over 35% in MAUs in
- As per Financial Express, the share of failed auto-debit requests on the National Automated Clearing House (NACH) platform eased to 29.21% in volume terms in February, down 43 bps from January. In value terms, the bounce rate was at 22.44%, down 99 bps from January. While these levels mark the lowest failure rates on EMI requests since the beginning of the pandemic in March 2020, some pockets of retail loans are still showing high delinquency rates

5Nifty Daily Chart NIFTY [N59901]16594.90, 2.15% Price Avg(E,52) LOG IRIS 19000 18000 16594 15000 14000 13000 12000 11000 10000 9000 8000 Source: www.SpiderSoftwareIndia.Com Stoch(5,3,5,3) 50.00 19:A O N D 20:J F M A M J J A S O N D 21:J F M A M J J A S O N D 22:J M Wkl

Pivot Points						
Index/Stocks	Trend	Close	S 1	S2	R1	R2
S&P BSE SENSEX INDEX	Positive	55464.4	54884	54303	56143	56823
NIFTY 50	Positive	16594.9	16443	16291	16752	16909
AARTI INDUS LTD	Positive	828.0	809	791	854	881
ASIAN PAINTS LTD	Positive	2912.8	2856	2799	3005	3097
DIVI LABS LTD	Positive	4300.9	4258	4214	4340	4378
STATE BANK IND	Positive	468.7	461	454	476	484
DR REDDY'S LABS	Neutral	3892.5	3850	3807	3960	4029
IPCA LABS LTD	Negative	1001.5	989	975	1020	1037
TATA MOTORS LTD	Positive	419.6	411	402	432	444
INDUSIND BANK	Positive	904.3	888	871	925	945
BATA INDIA LTD	Positive	1809.0	1788	1768	1833	1858
TATA CONSULTANCY	Positive	3621.0	3596	3571	3665	3709
GRANULES INDIA	Positive	292.7	289	283	301	307
BHARAT PETROL	Positive	349.0	346	342	355	359
INDIAN RAILWAY C	Positive	758.1	748	738	770	782
RELIANCE INDS	Positive	2392.3	2367	2341	2412	2431
AU SMALL FINANCE	Positive	1162.1	1143	1125	1187	1213
CESC LTD	Positive	79.2	78	77	79	81

Nifty Call - Put Strike (Number of shares in lakh) - February, 2022



Technical Outlook

Equity benchmarks endured its winning streak over third consecutive session tracking firm global cues amid cool off in crude oil and VIX. Further, market sentiment boosted by the state election result. The Nifty concluded weekly expiry session at 16595, up 250 points or 1.5%. In the coming session, index is likely to open on a negative note tracking muted global cues. We believe, retracement of past three session sharp up move will make market healthy. Thus, after an initial blip we expect buying demand to emerge around intraday support of 16400. Hence, use dips towards 16430-16460 for creating long position for target of 16547

Going ahead, 16800 would be the key level to watch as a decisive close above 16800 would open the door for next leg of up move towards 17200 in coming weeks. Else couple of days breather cannot be ruled out after past three sessions ~1100 points sharp up move. Thus any dip from hereon should not be construed as negative. Instead it should be capitalized as buying opportunity.

CNX Nifty Technical Picture						
	Intraday	Short term				
Trend	Range Bound	Range Bound				
Support	16450-16340	15900				
Resistance	16620-16700	16800				
20 day EMA		16732				
200 day EMA		16694				

Advance	s/Declines		
	Advances	Declines	Unchanged
BSE	2423	941	96
NSF	1457	626	44

Daily Technical Calls Daily Technical Calls

- 1. Buy NMDC in the range 152.50-153.50
- 2. Buy Chambal Fertiliser in the range of 413.00-415.00

All recommendations of February Future

See Momentum Pick for more details

Ш	ure	aday D	enval	ive	ouale	gy		
	١.	lindal	Stool .	G D	lower	Limitad	/CMD.	46

i) Jindal Steel & Power Limited (CMP: 465.05) Buy JINSP December Fut at ₹ 464.55-465.55 Target 1: 468.7 Target 2: 474.1 Stop Loss: 461.5

ii) Coforge (CMP: 4279.75) Sell NIITEC December Fut at ₹ 4276.75-4282.75 Target 1: 4189.8 Target 2: 4054.8 Stop Loss: 4369.8

See Derivatives view for more details





Results/E	vents Calendar										
21	February Monday	22 Mahindra CIE	February Tuesday	23 Sanofi India	February Wednesday	24	February Thursday	25	February Friday	26	February Saturday
EU Service PN EU Composite EU Manufactu	e PMI	US Service Pl USComposite US Manufact	PMI	EU CPI		JP CPI US GDP					
28	February Monday	01	March Tuesday	02	March Wednesday	03	March Thursday	04	March Friday	05	March Saturday
CH Manufacti IN Infrastruct IN GDP Annua IN Federal Fis	cure Output al, GDP Quarterly	US Manufact UK Manufact EU Manufact	uring PMI	IN Markit Ma JP Services F EU CPI	nunfacturing PMI PMI	US Service PI UK Composit Eu Unemployi EU Composit	e PMI ment Rate	IN Nekkei Ser UK Constructi EU Retail Sale US Enemployi	on PMI s		
07	March Monday	08	March Tuesday	09	March Wednesday	10	March Thursday	11	March Friday	12	March Saturday
CH FX Resev	e	EU Unemploy EU GDP YoY US Trade Bal JP GDP QoQ CH CPI YoY	ment Change	JP PPI YoY		US CPI YoY US Federal B	udget Balance	IN Industrial F IN Manufactu			·
14	March Monday	15	March Tuesday	16	March Wednesday	17	March Thursday	18	March Friday	19	March Saturday
IN WPI Food IN WPI Fuel IN WPI Inflati IN WPI Manu IN CPI	ion Ifacturing Inflation	CH Industrial UK Unemploy EU Industrial US PPI JP Trade Bala	rment Rate Production	US Retail Sali US Fed Intere	es sst Rate Decision	EU CPI UK Interest R US Industrial JP CPI		EU Trade Bala Existing Home			
21	March Monday	22	March Tuesday	23	March Wednesday	24	March Thursday	25	March Friday	26	March Saturday
		EU Current A UK Public Sec EU Construct	ctor Net Borrowing	UK Core PPI OUK Annual BU US New Hom EU Consumer	dget Release e Sales	1	ccount	US Pending H		CH Industrial	Profits YoY

Maior Economic Events this Week							
Date	Event	Country	Period	Actual	Expected		
04-Mar	Nikkei Services PMI	IN	Feb	51.8	53.0		
04-Mar	FX Reserves, USD	IN	Feb	631.53	-		
07-Mar	FX Reserves (USD)	CH	Feb	3.214T	3.225T		
08-Feb	Employment Change	EU	Q 4	2.20%	2.10%		
08-Feb	GDP Quarterly	EU	Ω4	0.30%	0.30%		
08-Feb	Trade Balance	US	Mar	-89.70B	-87.10B		
08-Feb	CPI (MoM)	CH	Feb	0.60%	0.30%		
09-Mar	M3 Money Supply	IN	Mar	8.70%	9.00%		
09-Mar	Crude Oil Inventory	US	Mar	-1.863M	-0.657M		
09-Mar	JOLTs Job Openings	US	Mar	11.263M	10.925M		
10-Mar	Core CPI	US	Feb	0.50%	0.50%		
10-Mar	Initial Jobless Claims	US	Feb	227K	217K		
10-Mar	Deposit Facility Rate	EU	Mar	-0.50%	-0.50%		
Date	Event	Country	Period	Expected	Previous		
11-Mar	Cumulative Industrial Production	IN	Mar	-	15.20%		
11-Mar	Industrial Production	IN	Mar	1.30%	0.40%		
11-Mar	Manufacturing Output	IN	Mar	-	-0.10%		

Bulk Deals						
/ Company	Client Name	Type	No. of shares	Price (₹)		
NSE						
Nureca Limited	NEXPACT LIMITED	SELL	54,914	1504		

Recent Releases				
Date	Report			
March 10, 2022	Initiating Coverage- GR Infraprojects Lt			
March 07, 2022	Sector Update- Oil & Gas			
March 04, 2022	Company Update- Biocon			
March 03, 2022	Company Update- Pricol Ltd			
March 02, 2022	Company Update- Huhtamaki India			





Pankaj Pandey

Head – Research pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC Andheri (East) Mumbai – 400 093 research@icicidirect.com



Disclaimer

ANALYST CERTIFICATION

I/We, Pankaj Pandey, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICl Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICl Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.